Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome

Autor según el artículo: Bouzas, Cristina; Pastor, Rosario; Garcia, Silvia; Monserrat-Mesquida, Margalida; Martinez-Gonzalez, Miguel Angel; Salas-Salvado, Jordi; Corella, Dolores; Goday, Albert; Martinez, J Alfredo; Alonso-Gomez, Angel M; Fernandez-Barcelo, Olga; Vioque, Jesus; Romaguera, Dora; Lopez-Miranda, Jose; Estruch, Ramon; Tinahones, Francisco J; Lapetra, Jose; Serra-Majema, Lluis; Riquelme-Gallegop, Blanca; Martin-Sanchez, Vicente; Pinto, Xavier; Delgado-Rodriguez, Miguel; Matia, Pilar; Vidal, Josep; Cardenas-Salas, Jersy-Jair; Daimiel, Lidia; Ros, Emilio; Toledo, Estefania; Manzanares, Josep M; Gonzalez-Monge, Inmaculada; Munoz, Miguel-Angel; Martinez-Urbistondo, Diego; Tojal-Sierra, Lucas; Munoz-Bravoaf, Carlos; Miralles-Gisbert, Salvador; Martin, Marian; Garcia-Rios, Antonio; Castro-Barquero, Sara; Fernandez-Garcia, Jose Carlos; Santos-Lozano, Jose Manuel; Basterra-Gortari, F Javier; Gutierrez-Carrasquilla, Liliana; Guillem-Saiz, Patricia; Satorres, Alba; Abete, Itziar; Sorto-Sanchez, Carolina; Diez-Espino, Javier; Babio, Nancy; Fito, Montse; Tur, Josep A

Departamento: Bioquímica i Biotecnologia

Autor/es de la URV: Babio Sánchez, Nancy Elvira / Manzanares Errazu, José María / Salas Salvadó, Jorge

Palabras clave: Metabolic syndrome; Glucagon-like peptide 1 agonists; Glp-1ra; Dpp-4i; Antidiabetic drug; 4-dipeptidyl peptidase inhibitors; sitagliptin; questionnaire; physical-activity; pharmacokinetics; medication; iv inhibitor; insulin; glucagon-like peptide 1 agonists; glp-1ra; glp-1; dpp-4i; double-blind; 4-dipeptidyl peptidase inhibitors

Resumen: To assess the comparative effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), 4-dipeptidyl peptidase inhibitors (DPP-4I), and metformin treatment during one year on metabolic syndrome (MetS) components and severity in MetS patients.Prospective study (n = 6165 adults) within the frame of PREDIMED-Plus trial. The major end-point was changes on MetS components and severity after one- year treatment of GLP-1RA, DPP-4I, and metformin. Anthropometric measurements (weight, height and waist circumference), body mass index (BM), and blood pressure were registered. Blood samples were collected after overnight fasting. Plasma glucose, glycosylated hemoglobin (HbA1c), plasma triglycerides and cholesterol were measured. Dietary intakes as well as physical activity were assessed through validated questionnaires.MetS parameters improved through time. The treated groups improved glycaemia compared with untreated (glycaemia ∆ untreated: -1.7 mg/dL(± 13.5); ∆ metformin: - 2.5(± 23.9) mg/dL; ∆ DPP-4I: - 4.5(± 42.6); mg/dL ∆ GLP-1RA: - 4.3(± 50.9) mg/dL; and HbA1c: ∆ untreated: 0.0(± 0.3) %; ∆ metformin: - 0.1(± 0.7) %; ∆ DPP-4I: - 0.1(± 1.0) %; ∆ GLP-1RA: - 0.2(± 1.2) %. Participants decreased BMI and waist circumference. GLP-1RA and DPP-4I participants registered the lowest decrease in BMI (∆ untreated: -0.8(± 1.6) kg/m2; ∆ metformin: - 0.8(± 1.5) kg/m2; ∆ DPP-4I: - 0.6(± 1.3) kg/m2; ∆ GLP-1RA: - 0.5(± 1.2) kg/m2. and their waist circumference (∆ untreated: -2.8(± 5.2) cm; ∆ metformin: - 2.6(± 15.2) cm; ∆ DPP-4I: - 2.1(± 4.8) cm; ∆ GLP-1RA: - 2.4(± 4.1) cm.In patients with MetS and healthy lifestyle intervention, those treated with GLP-1RA and DPP-4I obtained better glycemic profile. Anthropometric improvements were modest.Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Áreas temáticas: Saúde coletiva; Química; Pharmacology & pharmacy; Pharmacology; Odontología; Medicine, research & experimental; Medicine (miscellaneous); Medicina veterinaria; Medicina iii; Medicina ii; Medicina i; Materiais; Interdisciplinar; Farmacia; Engenharias iii; Engenharias ii; Enfermagem; Educação física; Ciências biológicas iii; Ciências biológicas ii; Ciências biológicas i; Ciências agrárias i; Ciência de alimentos; Ciência da computação; Biotecnología; Biodiversidade; Astronomia / física

Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/

Direcció de correo del autor: josemaria.manzanares@urv.cat; jordi.salas@urv.cat; josemaria.manzanares@urv.cat; nancy.babio@urv.cat

Fecha de alta del registro: 2025-02-19

Versión del articulo depositado: info:eu-repo/semantics/publishedVersion

Enlace a la fuente original: https://www.sciencedirect.com/science/article/pii/S0753332223003499?via%3Dihub

URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/

Referencia al articulo segun fuente origial: Biomedicine & Pharmacotherapy. 161 114561-114561

Referencia de l'ítem segons les normes APA: Bouzas, Cristina; Pastor, Rosario; Garcia, Silvia; Monserrat-Mesquida, Margalida; Martinez-Gonzalez, Miguel Angel; Salas-Salvado, Jordi; Corella, Dolo (2023). Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome. Biomedicine & Pharmacotherapy, 161(), 114561-114561. DOI: 10.1016/j.biopha.2023.114561

DOI del artículo: 10.1016/j.biopha.2023.114561

Entidad: Universitat Rovira i Virgili

Año de publicación de la revista: 2023

Tipo de publicación: Journal Publications